RIGLRigel Pharmaceuticals

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress PR Newswire SOUTH SAN FRANCISCO, Calif., May 21, 2026 Oral presentation at ASCO Annual Meeting to...

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif...

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.read more...

Rigel Pharmaceuticals signed a global licensing deal with Arvinas and Pfizer for an advanced breast cancer treatment.

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture and commercialize beast cancer treatment Veppanu...

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer Rigel Enters Exclusive...

Rigel Pharmaceuticals (NASDAQ:RIGL) reported first-quarter 2026 results that management said reflected continued year-over-year growth across its three-product portfolio, while reiterating full-year guidance and highlighting upcoming data milestones for its R289 program in lower-risk myelodysplastic...

(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) announced earnings for first quarter that Dropped, from last year...

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) released its earnings results on Tuesday. The biotechnology company reported $0.44 EPS for the quarter, missing analysts' consensus estimates of $0.80 by ($0.36). The firm had revenue of $58.82 million during the quarter, compared to analysts...